Table of content

I  Original publications within this habilitation theses p. 4

II  List of abbreviations p. 6

1  Introduction p. 7

1.1  Atherosclerosis as main cause of cardiovascular diseases p. 7

1.2  Chemokines in inflammation and atherosclerosis p. 9

1.2.1  CCL2-CCR2 axis p. 9

1.2.2  CCL5-CCR5/CCR1 axis p. 10

1.2.3  CCL12-CXCR4/ACKR3 axis p. 11

1.3  Adipose tissue as diver of atherosclerosis p. 13

1.3.1  Chemokines and AT lipid accumulation and inflammation p. 14

1.3.2  The calcium-sensing receptor and AT lipid accumulation and inflammation p. 15

1.4  MicroRNA-26b as regulator of platelet adhesion and thrombosis p. 16

1.5  AMI as clinical outcome of atherosclerosis development p. 18

1.6  PCSK9 as novel therapeutic approach p. 20

2  Aims of this habilitation thesis p. 22

3  Results p. 24

3.1  Reference I: CXCL12 derived from endothelial cells promotes atherosclerosis to drive coronary artery disease. p. 24

3.2  Reference II: B-cell specific CXCR4 protects against atherosclerosis development and increases plasma IgM levels. p. 25

3.3  Reference III: Endothelial ACKR3 drives atherosclerosis by promoting immune cell adhesion to vascular endothelium. p. 26

3.4  Reference IV: Adipocyte-specific ACKR3 regulates lipid levels in adipose tissue. p. 27

3.5  Reference V: Adipocyte calcium sensing receptor is not involved in visceral adipose tissue inflammation or atherosclerosis development in hyperlipidemic Apoe<sup>−/−</sup> mice. p. 28

3.6  Reference VI: MicroRNA-26b attenuates platelet adhesion and aggregation in mice. p. 29

3.7  Reference VII: CCR6 deficiency increases infarct size after murine acute myocardial infarction. p. 30

3.8  Reference VIII: PCSK9 imperceptibly affects chemokine receptor expression in-vitro and in-vivo. p. 31